Comparative Pharmacology
Head-to-head clinical analysis: INDICLOR versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDICLOR versus NAPROXEN SODIUM.
INDICLOR vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
INDICLOR is not a recognized drug; no standard dosing available.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID